Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson's Disease: A Systematic Review and Meta-Analysis

Chung, Chloe Lau Ha; Mak, Kit Yi

doi:10.1016/j.brs.2016.03.017

Cited by 73 publications

(70 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our subgroup analysis showed the effect size was statistically significant for trials of multiple sessions with higher number of total stimulation pulses (range from 18,000 to 20,000 pulses). This is in line with an earlier review that indicates a larger effect size of rTMS on UPDRS‐III scores is associated with a greater number of stimulation pulses (Chung & Mak, ). One study of rTMS on major depression showed that 1,200–1,500 pulses/day for 10 or 20 sessions (a total of dose between 12,000 and 30,000 pulses) had the best anxiolytic effects (Teng et al., ).…”

Section: Discussionsupporting

confidence: 91%

“…In addition, rTMS over the M1 is more effective than stimulation over the SMA. A previous study gained the similar result (Chung & Mak, ). Moreover, Zanjani et al.…”

Section: Discussionsupporting

confidence: 81%

“…Who found a significant effect size of UPDRS‐III for HF‐rTMS studies but not significant for LF‐rTMS studies. Distinct results, however, were observed in some other meta‐analysis studies in which no significant difference between HF‐rTMS and LF‐rTMS was found (Chou et al., ); an opposite result was discovered (Wagle Shukla et al., ) or no significant result was observed both in HF‐rTMS and LF‐rTMS (Chung & Mak, ). The reasons for these distinctions may be due to the differences in the included trials, (Zhu et al., ) data extraction, (Chou et al., ) and statistical methods (Wagle Shukla et al., ).…”

Section: Discussionmentioning

confidence: 94%

“…Previous studies evaluated the long‐term effect of rTMS on motor function in PD patients (Chou et al., ; Chung & Mak, ; Wagle Shukla et al., ; Zanjani et al., ). Chou et al.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta‐analysis

et al. 2018

View full text Add to dashboard Cite

IntroductionTherapeutic effects of repetitive transcranial magnetic stimulation (rTMS) on motor recovery of Parkinson's disease (PD) have been reported; however, the protocols of these studies varied greatly. The aim of this meta‐analysis was to evaluate the optimal rTMS parameters for motor recovery of PD.MethodsElectronic databases were searched for studies investigating the therapeutic effects of rTMS on motor function in patients with PD. The section III of the Unified Parkinson's Disease Rating Scale (UPDRS) was extracted as the primary outcome, and the standardized mean difference (SMD) with 95% confidence interval (CI) was calculated.ResultsTwenty‐three studies with a total of 646 participants were included. The pooled estimates of rTMS revealed significant short‐term (SMD, 0.37; p < 0.00001) and long‐term (SMD, 0.39; p = 0.005) effects on motor function improvement of PD. Subgroup analysis observed that high‐frequency rTMS (HF‐rTMS) was significant in improving motor function (SMD, 0.48; p < 0.00001), but low‐frequency rTMS (LF‐rTMS) was not. In particular, when HF‐rTMS targeted over the primary motor cortex (M1), in which the bilateral M1 revealed a larger effect size than unilateral M1. Compared to single‐session, multi‐session of HF‐rTMS over the M1 showed significant effect size. In addition, HF‐rTMS over the M1 with a total of 18,000–20,000 stimulation pulses yielded more significant effects (SMD, 0.97; p = 0.01) than other dosages.ConclusionsIn conclusion, multi‐session of HF‐rTMS over the M1 (especially bilateral M1) with a total of 18,000–20,000 pulses appears to be the optimal parameters for motor improvement of PD.

show abstract

Section: Discussionsupporting

confidence: 91%

“…In addition, rTMS over the M1 is more effective than stimulation over the SMA. A previous study gained the similar result (Chung & Mak, ). Moreover, Zanjani et al.…”

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 94%

“…Previous studies evaluated the long‐term effect of rTMS on motor function in PD patients (Chou et al., ; Chung & Mak, ; Wagle Shukla et al., ; Zanjani et al., ). Chou et al.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta‐analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Accordingly, it is necessary to identify the use of LP in the PD's treatment and to determine the pharmacoeconomic studies' quality that has been done in the last five years. In the literature exists multiple systematic reviews of Parkinson's disease and others associated with the disease treatment [14][15][16][17][18][19][20][21]. But, there are not quality evaluations of the publication's methodology focused on cost-utility studies of the LD used in the EP treatment.…”

Section: Introductionmentioning

confidence: 99%

The assessment of pharmacoeconomic studies quality of Levodopa’s use for the management of Parkinson’s diseases, 2010-2015

Gutiérrez

Becerra

Rojas

2017

Rev. colomb. cienc. quim. farm.

View full text Add to dashboard Cite

SummaryLevodopa (LD) has been the first choice in the management of Parkinson's disease (PD), since its introduction in the drug market; however, its prolonged use is related to the occurrence of motor complications, affecting the functionality and quality of life. Parkinson's disease is one of the most frequent among the neurodegenerative diseases in the world, and it is expected that the number of people who suffer it, will increase due to global population aging. The PD represents, nowadays and for the future, a high economic burden from all perspectives, including patients, payers, and society. So it is necessary to know about the use of LD in its treatment and to realize the quality of pharmacoeconomic studies in the past five years, to identify reliable sources of information related to the costs and benefits of this medication to contribute in making decisions. The aim of this paper is to assess the methodological quality of pharmacoeconomic studies related to the use of LD in PD, specifically those that are identified as cost-utility studies, applying the QHES instrument. A total of 19 articles were found, of which 5 met the inclusion criteria and were subjected to examination. The average overall score obtained after the evaluation was 77.2 out of 100, making evident a good quality of studies according to the method used.Keywords: Levodopa, Parkinson's disease, cost-utility, methodological quality, QHES (Quality of Health Economic Studies). La Levodopa (LD) ha sido desde su introducción en el mercado la primera elección en el manejo de la enfermedad de Parkinson (EP); sin embargo, su uso prolongado está relacionado con la aparición de complicaciones motoras, afectándose la funcionalidad y calidad de vida. La EP es una de las enfermedades neurodegenerativas que se presenta con mayor frecuencia en el mundo y se espera que el número de personas que la padecen aumente, debido al envejecimiento poblacional a nivel mundial. La EP representa, actualmente y a futuro, una alta carga económica desde todas las perspectivas, incluyendo: pacientes, pagadores y la sociedad; por lo cual es necesario conocer el uso de la LD en el tratamiento de la misma y lograr determinar la calidad de los estudios farmacoeconómicos realizados en los últimos cinco años, para identificar fuentes fiables de información relacionadas con los costos y los beneficios de este medicamento que aporten en la toma de decisiones. El objetivo de este artículo es evaluar la calidad metodológica de los estudios farmacoeconómicos relacionados con el uso de la LD en la EP, específicamente aquellos que se cataloguen como estudios de costo-utilidad, aplicando el instrumento QHES. Se encontraron en total 19 artículos, de los cuales cinco cumplieron los criterios de inclusión y fueron sometidos al respectivo análisis. El puntaje global promedio obtenido posterior a la evaluación fue de 77,2 sobre 100, haciendo evidente una buena calidad de los estudios de acuerdo con el método utilizado.Palabras clave: Levodopa, enfermedad de Parkinson, costo-utilidad, ca...

show abstract

Textile Electronics for VR/AR Applications

Liu

Bao

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Textile electronics addresses fibers or fiber assemblies with electronic functions to generate, transmit, modulate, and detect electrons. Interactive textile electronic devices may provide suitable platforms for virtual reality (VR)/augmented reality (AR) applications because of their excellent performance and unique immersive features such as lightweight, handiness, flexibility, comfort, and low strain even under high deformations. This paper presents a systematic review of the literature on the state‐of‐the‐art of interactive devices, fabrication technologies, system integration, promising applications, and challenges involved in textile‐based VR/AR systems.

show abstract

Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson's Disease: A Systematic Review and Meta-Analysis

Cited by 73 publications

References 71 publications

Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta‐analysis

Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta‐analysis

The assessment of pharmacoeconomic studies quality of Levodopa’s use for the management of Parkinson’s diseases, 2010-2015

Textile Electronics for VR/AR Applications

Contact Info

Product

Resources

About